Toku Inc. announced last week it received US Food and Drug Administration breakthrough device designation for its MyKidneyAI technology, which uses AI to analyze retinal images at routine eye exams to detect elevated chronic kidney disease risk in people with diabetes.
News We’re Watching: Philips Settles Recall Fallout; FDA REdI, Townhalls, Approvals
This week, Philips Respironics reached a $1.1b settlement affecting CPAP and other breathing devices. Toku announced it received US FDA breakthrough device designation for its MyKidneyAI technology. This May, the FDA will hold its REdI conference focusing on innovation in medical product development and hold another townhall focusing on considerations for selecting a sterilization modality.
